ストックスクリーナーアプリを入手
22.79
0.80%
-0.27
前日終値:
$23.06
開ける：
$23.87
24時間の取引高:
776.76K
Relative Volume:
0.37
時価総額：
$17.01B
収益：
$956.00K
当期純損益:
$-196.68M
株価収益率:
-94.96
EPS:
-0.24
ネットキャッシュフロー:
$-113.02M
1週間 パフォーマンス:
+7.04%
1か月 パフォーマンス:
+3.51%
6か月 パフォーマンス:
+71.48%
1年 パフォーマンス:
+456.57%
1日の値動き範囲:
$22.72
$24.18
1週間の範囲:
$20.43
$24.18
52週間の値動き範囲:
$2.10
$33.89
Summit Therapeutics Inc Stock (SMMT) Company Profile
SMMT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
22.77 | 17.01B | 956.00K | -196.68M | -113.02M | -0.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.00 | 123.34B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
696.64 | 76.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
648.37 | 39.34B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.98 | 32.49B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
117.05 | 28.26B | 3.30B | -501.07M | 1.03B | -2.1146 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-08 | 開始されました | Truist | Buy |
| 2024-12-11 | 開始されました | Wells Fargo | Overweight |
| 2024-12-06 | 開始されました | Jefferies | Buy |
| 2024-11-04 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-09-27 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-08-12 | 開始されました | H.C. Wainwright | Buy |
| 2024-05-07 | 開始されました | Citigroup | Buy |
| 2024-03-26 | 開始されました | Stifel | Buy |
| 2018-06-28 | ダウングレード | Janney | Buy → Neutral |
| 2018-05-02 | 開始されました | Janney | Buy |
| 2018-04-12 | 繰り返されました | Needham | Buy |
| 2018-02-13 | 開始されました | BTIG Research | Buy |
| 2018-01-04 | 開始されました | SunTrust | Buy |
| 2017-12-01 | 再開されました | H.C. Wainwright | Buy |
| 2016-11-16 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2016-10-05 | 繰り返されました | Needham | Buy |
| 2016-09-16 | 開始されました | H.C. Wainwright | Buy |
| 2015-03-30 | 開始されました | Needham | Buy |
| 2015-03-30 | 開始されました | Oppenheimer | Outperform |
すべてを表示
Summit Therapeutics Inc (SMMT) 最新ニュース
Summit Therapeutics Inc. (SMMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Summit Therapeutics (SMMT) Expected to Announce Earnings on Tuesday - MarketBeat
Summit Therapeutics Earnings: Critical Q4 Financial Report & Strategic Roadmap Reveal Coming February 24 - StockTitan
Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 6.8%Time to Sell? - MarketBeat
3 Stocks That Could Trounce the Market in 2025 - Yahoo Finance
Summit Therapeutics (NASDAQ:SMMT) Shares Down 6.8%Here's What Happened - MarketBeat
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
U.S. investors, Big Pharma race to find new medicines in China - CNBC
Summit Therapeutics (NASDAQ:SMMT) Shares Up 6%Here's Why - MarketBeat
SG Americas Securities LLC Sells 19,587 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
When the Price of (SMMT) Talks, People Listen - Stock Traders Daily
abrdn plc Increases Stock Position in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Mid-Cap Biopharma’s Biggest Winners And Losers Of 2024 - Citeline News & Insights
Calamos Advisors LLC Has $425,000 Position in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Is Summit Therapeutics a Millionaire Maker? - Nasdaq
2 Stocks That Could Soar Again in 2025 - MSN
Why Summit Therapeutics Inc. (SMMT) Is Among the Best Healthcare Stocks To Buy According to Analysts - Insider Monkey
Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 5.4%Should You Sell? - MarketBeat
The drug industry is having its own DeepSeek moment | Mint - Mint
The Drug Industry Is Having Its Own DeepSeek Moment - The Wall Street Journal
China Universal Asset Management Co. Ltd. Acquires 17,014 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Summit Therapeutics Inc. (NASDAQ:SMMT) Receives $33.57 Average Price Target from Brokerages - MarketBeat
Five Pine Wealth Management Makes New Investment in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Summit Therapeutics (SMMT): Jim Cramer Calls It a ‘Very Big Spec’ - Insider Monkey
Jim Cramer Says AppFolio Is A 'Good One,' But Summit Therapeutics? 'Can't Go There' - Benzinga India
Summit Therapeutics Inc. (NASDAQ:SMMT) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Up More Than 500% in 12 Months, Is It Too Late to Buy Summit Therapeutics Stock? - MSN
Griffin Asset Management Inc. Purchases 42,900 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Lightning Round: I don't want to sell Adobe down here, says Jim Cramer - MSN
(SMMT) Investment Report - Stock Traders Daily
Is Summit Therapeutics Inc. (SMMT) the Unstoppable Stock to Buy in 2025? - Yahoo Finance
Why This Beaten-Down Stock Is a Buy in 2025 and Beyond - The Motley Fool
Summit Therapeutics Inc (SMMT) 財務データ
収益
当期純利益
現金流量
EPS
0.48%
0.42%
大文字化:
|
ボリューム (24 時間):